If you have diabetes and are taking insulin or sulfonylureas alongside GLP-1 therapy, be alert for hypoglycaemia symptoms and discuss dose adjustments with your healthcare team
There may be one area or areas you feel most comfortable injecting into and its completely fine to stick to those area(s), but keep in mind that you should be rotating the exact area where you inject to avoid reactions and discomfort this is key to minimizing side effects
Our data provide a rational template to facilitate the design of better GLP-2 analogues for therapeutic use and expand our knowledge on the biology of this receptor family
Recommended Stack: GHK-Cu topical scalp application (daily) + injectable if desired BPC-157 promotes vascularization and reduces perifollicular inflammation TB500 enhances follicle stem cell activity and tissue remodeling CJC-1295 + Ipamorelin (optional) supports systemic IGF-1 for hair growth phase prolongation Duration: 1216 weeks (hair growth cycles are slower than skin) Maintenance: Continue GHK-Cu topical + BPC-157 support Scar Healing and Post-Procedure Stack Goal: Accelerate skin healing , minimize scarring , improve skin texture after: Laser resurfacing Surgery Microneedling Chemical peels Recommended Stack: BPC-157 daily systemic for 46 weeks post-procedure TB500 25 mg/week loading, then maintenance to support soft tissue healing GHK-Cu topical application to treated area + optional injectable for deep scars CJC-1295 + Ipamorelin accelerates collagen and elastin rebuilding Duration: 48 weeks depending on procedure type and depth of tissue injury Maintenance: GHK-Cu topical continued long-term on scar-prone areas Combining peptides that stimulate collagen synthesis, angiogenesis, and cellular regeneration produces synergistic effects superior to monotherapy in skin and hair applications. Gentile et al., Dermatologic Surgery Legal Status and Disclaimer Before using any of the peptides discussed in this guide including BPC-157 , TB500 , CJC-1295 , Ipamorelin , GHK-Cu , and Epithalon it is essential to understand their current legal status and regulatory considerations
(C, D) Schedules of human L-Cn challenge test
